NCT05280184 (Coin2Dose) is a NA clinical trial of Coin2Dose in Type 1 Diabetes, sponsored by Nemours Children's Clinic.

Who is sponsoring NCT05280184?

NCT05280184 is sponsored by Nemours Children's Clinic.

What drugs are being tested in NCT05280184?

Interventions in NCT05280184: Coin2Dose.

What condition does NCT05280184 study?

NCT05280184 studies Type 1 Diabetes.

Is NCT05280184 still recruiting?

NCT05280184 is currently completed. Last updated 11 February 2026.

Are results published for NCT05280184?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2026-02-11 · How we verify

NCT05280184: Coin2Dose

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Coin2Dose: Behavioral Economics to Promote Insulin BOLUS Activity and Improve HbA1c in Teens

Completed NA Results posted Last updated 11 February 2026

What this trial tests

NA trial testing Coin2Dose in Type 1 Diabetes in 173 participants. Completed in 30 September 2025.

Timeline

1 January 2023

Primary endpoint
30 June 2025

30 September 2025

Quick facts

Lead sponsor	Nemours Children's Clinic
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	173
Start date	1 January 2023
Primary completion	30 June 2025
Estimated completion	30 September 2025
Sites	2 locations across United States

Drugs / interventions tested

Coin2Dose

Conditions studied

Type 1 Diabetes — all drugs for Type 1 Diabetes →

Sponsor

Nemours Children's Clinic

Who can join

Adults 11 to 17, any sex, with Type 1 Diabetes. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Change in Glycated Hemoglobin- HbA1c Primary · change in week 0 outcome at week 13

proxy measure of average glycemic levels

Group	Value	95% CI
Standard Care	-0.14	± 0.58
Coin2Dose	-0.09	± 0.65

Change in Daily Insulin Bolus Score Primary · change in week 0 outcome at week 13

valid, objective measure of insulin use in youth with type 1 diabetes; range 0-3, higher scores reflect greater adherence to mealtime insulin use

Group	Value	95% CI
Standard Care	-0.11	± 0.56
Coin2Dose	-0.08	± 0.66

Sponsor's own description

Our objective is to test the feasibility, acceptability, and initial efficacy of using behavioral economics incentives (BEI) in a novel, semi-automated intervention to target daily insulin BOLUS scores in adolescents with suboptimal insulin use.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Type 1 Diabetes

Currently open trials in the same condition.

NCT07061574 — A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New On · Phase 1, PHASE2 · recruiting
NCT07360080 — Long-Term Outcomes of Teplizumab in Routine Clinical Care · recruiting
NCT07457580 — Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs) · recruiting
NCT07212179 — Safety and Feasibility of a Self-Learning Bolus Calculator With Simplified Meal Announcement in Adolescents With Type 1 · NA · recruiting
NCT07287943 — To Study the Efficacy and Safety of Medtronic 780G Insulin Pump in People With Gastroparesis and Type 1 Diabetes. · NA · recruiting

Other Nemours Children's Clinic trials

Trials by the same sponsor.

NCT06616818 — DASH Diet Intervention for Systemic Hypertension in Adolescents · NA · withdrawn
NCT07218588 — Sanctuary Farm Prescription in Adolescents · NA · recruiting
NCT06406621 — Pilot Trial Assessing the Effectiveness of Laser Hair Depilation on Pilonidal Disease Recurrence in Patients With Darker · NA · recruiting
NCT07154667 — Evaluation of the Auryzon™ EAR 2.0 System in Ear Reconstruction · NA · recruiting
NCT07212049 — Ultrasound Use to Measure Magnetically Controlled Growing Rods · NA · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05280184 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nemours Children's Clinic
Last refreshed: 11 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05280184.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing